E Mis Amy Dyken, controller at Kingbird Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Kingbird's financial statements. Below is selected financial information for the fiscal year ended June 30, 2020. Kingbird Pharmaceutical Industries Long-term debt Notes payable, 10% 8% convertible bonds payable 10% bonds payable Total long-term debt Shareholders' equity Selected Balance Sheet Information June 30, 2020 $990,000 5,030,000 5,880,000 $11,900,000 Preferred stock, 5% cumulative, $50 par value, 107,000 shares authorized, 26,750 shares issued and outstanding $1,337,500 Res